These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18953270)

  • 21. [HIV infection: entry and integrase inhibitors].
    Med Monatsschr Pharm; 2007 Nov; 30(11):393. PubMed ID: 18062329
    [No Abstract]   [Full Text] [Related]  

  • 22. The pipeline: three to watch.
    Hawes J
    BETA; 2004; 16(4):13-5. PubMed ID: 15386838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral drug resistance and fitness.
    Quiñones-Mateu ME; Moore-Dudley DM; Jegede O; Weber J; J Arts E
    Adv Pharmacol; 2008; 56():257-96. PubMed ID: 18086415
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiretroviral therapy in HIV.
    Yu A; Berbari E; Temesgen Z
    J Med Liban; 2006; 54(2):74-9. PubMed ID: 17086997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):563-9; quiz 569-70. PubMed ID: 20846564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: the development of novel inhibitors for the treatment of HIV infection.
    Tan JJ; Wang CX
    Curr Pharm Des; 2013; 19(10):1765-6. PubMed ID: 23092285
    [No Abstract]   [Full Text] [Related]  

  • 28. New drugs for HIV therapy.
    Rockstroh JK
    J HIV Ther; 2005 Dec; 10(4):66-7. PubMed ID: 16519244
    [No Abstract]   [Full Text] [Related]  

  • 29. [Resistance to protease inhibitors: the burden of mutations].
    Marcelin AG
    Med Mal Infect; 2006 Jul; 36 Suppl 2():S198-205. PubMed ID: 17075997
    [No Abstract]   [Full Text] [Related]  

  • 30. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-HIV agents. New and different drugs tested in people.
    TreatmentUpdate; 2004 Mar; 16(2):1-2. PubMed ID: 17219665
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-HIV therapy: Current and future directions.
    Agrawal L; Lu X; Jin Q; Alkhatib G
    Curr Pharm Des; 2006; 12(16):2031-55. PubMed ID: 16787246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV drug resistance.
    Calmy A; Pascual F; Ford N
    N Engl J Med; 2004 Jun; 350(26):2720-1. PubMed ID: 15215494
    [No Abstract]   [Full Text] [Related]  

  • 35. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-HIV agents. Leading to lipodystrophy.
    TreatmentUpdate; 2007 Feb; 19(2):3-4. PubMed ID: 17447312
    [No Abstract]   [Full Text] [Related]  

  • 37. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 38. Report from Buenos Aires on new drugs.
    Gallant JE
    Hopkins HIV Rep; 2001 Sep; 13(5):8, 16. PubMed ID: 11682859
    [No Abstract]   [Full Text] [Related]  

  • 39. Revised U.S. adult and adolescent antiretroviral treatment guidelines; also revised pediatric guidelines.
    AIDS Treat News; 2003 Nov; (396):4-5. PubMed ID: 14717112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Report from Boston: the 12th Conference on Retroviruses and Opportunistic Infections (CROI). New drugs, new targets: good news on the horizon.
    Flexner C
    Hopkins HIV Rep; 2005 Mar; 17(2):8-9. PubMed ID: 16419318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.